People who are witnessed by a bed partner to have stopped breathing during sleep may have higher accumulations of an Alzheimer’s disease biomarker called tau in an area of the brain that helps with memory, according to a preliminary study that will be presented at the American Academy of Neurology’s 71st Annual Meeting in Philadelphia, May 4 to 10, 2019.
“A person normally has fewer than 5 episodes of apnea per hour during sleep,” says study author Diego Z. Carvalho, MD, of the Mayo Clinic in Rochester, Minn, and a member of the American Academy of Neurology, in a release. “Bed partners are more likely to notice these episodes when people stop breathing several times per hour during sleep, raising concern for obstructive sleep apnea. Recent research has linked sleep apnea to an increased risk of dementia, so our study sought to investigate whether witnessed apneas during sleep may be linked to tau protein deposition in the brain.”
The study involved 288 people age 65 and older who did not have cognitive impairment. Bed partners were asked whether they had witnessed episodes of stopped breathing during sleep.
Participants had positron emission tomography (PET) brain scans to look for accumulation of tau tangles in the entorhinal cortex area of the brain, an area of the brain in the temporal lobe that is more likely to accumulate tau than some other areas. This area of the brain helps manage memory, navigation, and perception of time.
Researchers identified 43 participants, 15% of the study group, whose bed partners witnessed apneas when they were sleeping.
Researchers found those who had apneas had on average 4.5% higher levels of tau in the entorhinal cortex than those who did not have apneas, after controlling for several other factors that could affect levels of tau in the brain, such as age, sex, education, cardiovascular risk factors, and other sleep complaints.
“Our research results raise the possibility that sleep apnea affects tau accumulation,” says Carvalho. “But it’s also possible that higher levels of tau in other regions may predispose a person to sleep apnea, so longer studies are now needed to solve this chicken and egg problem.”
Limitations of the study included its relatively small sample size and preliminary nature of the study requiring future validation. Furthermore, a lack of sleep studies to confirm the presence and severity of sleep apnea and a lack of information regarding whether participants were already receiving treatment for sleep apnea is another serious limitation.
This limited study tends to show a long suspected link between sleep apnoea and Alzheimer’s disease. Unfortunately the louder message is that Government needs to fund clinical trials on sleep apnoea. There should be 2 control groups comprising one group using CPAP and the other group being taught Buteyko Breathing. Comparative sleep studies should be carried out before and after the clinical trial. Whatever the cost of carrying out the proposed clinical trial is dwarfed by the cost incurred by society through lost productivity as a result of this prevalent Sleep Disorder.